NF1 mutations as biomarker of response to immune checkpoint blockades for lung adenocarcinoma patients.
Jean-Stéphane GiraudAnne JouinotEric PasmantCamille TlemsaniPublished in: NPJ precision oncology (2024)
Little is known about immune checkpoint inhibitors (ICI) response of NF1-mutated lung adenocarcinomas. 341/4,181 (8.2%) TCGA lung adenocarcinomas samples have a somatic NF1 mutation. NF1-mutated tumors have higher TMB (p < 0.0001), higher expression of immune genes ("hot phenotype") and higher CD8 + T cell (p = 0.03) and macrophage (p = 0.02) infiltrations compared to NF1 wild-type tumors. NF1 mutation status appears as a candidate predictive biomarker for ICI response in lung adenocarcinoma patients.
Keyphrases
- signaling pathway
- lps induced
- end stage renal disease
- pi k akt
- nuclear factor
- oxidative stress
- wild type
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- inflammatory response
- adipose tissue
- cell proliferation
- immune response
- toll like receptor
- gene expression
- dna methylation
- transcription factor
- long non coding rna
- copy number